Fig. 15.
Potential therapeutic applications of the sequence-optimized designer peptides ≤ 30 amino acids composed of both coded and NCAAs. a Targeting the GLP-1R (wheat, PDB: 6XOX) through short designer peptide agonists (GLP-1 mimetic, salmon pink) for the management of T2DM, b Targeting the PPIs involving the G-protein subunits (Gα subunit, orange, PDB: 2ODE)] and the RGS protein through a designer peptide (pea green) inhibitor, c Targeting the PPIs involving the ACE2 receptor and the receptor-binding domain of the SARS-CoV2 spike protein (light pink, PDB: 6M0J) through designer small peptide inhibitors (blue), d Illustration of the membrane disruption potential of a designer small antimicrobial peptide (CPK) in the presence of a model POPC bilayer with a focus on the antimicrobial resistance (AMR), and e Design of antibody-like neutralizing peptide (yellow) targeting the complement protein C5a (brick red, PDB: 1KJS) for the treatment of chronic inflammation-induced diseases